secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001645113-24-000033
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NovoCure Q3 revenue +22% to $155M; FDA OKs Optune Lua; CEO/CFO transitions set
------------------------------------------------------------------------------

- Q3 net revenues $155.1M (+22% YoY); net loss $30.6M ($0.28 loss per share); adjusted EBITDA $1.7M.
- FDA approved Optune Lua for metastatic NSCLC; Breakthrough Device designation for brain metastases from NSCLC.
- CEO Asaf Danziger retiring Jan 1, 2025; CFO Ashley Cordova to become CEO on that date.
- Christoph Brackmann appointed CFO (from Moderna), effective Jan 1, 2025; compensation disclosed.
- Active patients on therapy 4,113; prescriptions up 8% to 1,586; cash and equivalents $959.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000033/0001645113-24-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000033/nvcr-20241029.htm
  HTML page:      https://secwatch.observer/filing/0001645113-24-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer